Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

CONCLUSIONSGuadecitabine has promising clinical activity and an acceptable safety profile and thus warrants further development in this population. Cancer 2017. © 2017 American Cancer Society.

Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Gail J. Roboz, Hagop M. Kantarjian, Karen W. L. Yee, Patricia L. Kropf, Casey L. O'Connell, Elizabeth A. Griffiths, Wendy Stock, Naval G. Daver, Elias Jabbour, Ellen K. Ritchie, Katherine J. Walsh, David Rizzieri, Scott D. Lunin, Tania Curio, Woonbok Chun Tags: Original Article Source Type: research